Christos Mikropoulos

Author

Royal Marsden NHS Foundation Trust ORCID

Also Known As

Alan Millner, C Mikropoulos, C. Mikropoulos, Christos Mikropoulos, Diane Long, The IMPACT study collaborators

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Royal Marsden NHS Foundation Trust Institute of Cancer Research University of Cambridge Guy's and St Thomas' NHS Foundation Trust University of Oxford

About

Christos Mikropoulos is an author at Royal Marsden NHS Foundation Trust specializing in medicine, cancer research, and molecular diagnostics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	253
2	Public Health	3	3	145
3	Health Sciences	1	1	20
4	Biostatistics	1	1	12
5	Epidemiology	1	1	12

Christos Mikropoulos

Publications

910

Citations

H-Index

Page 1

	Year	Citations
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers Elizabeth Page, Elizabeth Bancroft, Mark N. Brook, European Urology	2019	231
Prevalence of theHOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes Zsofia Kote‐Jarai, Christos Mikropoulos, Daniel Leongamornlert, Annals of Oncology UrologyOncologyCancer EpidemiologyCancer RiskMedicine	2015	97
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study Elizabeth Bancroft, Elizabeth Page, Mark N. Brook, The Lancet Oncology	2021	89
Microsatellite Instability Testing in Colorectal Patients with Lynch Syndrome: Lessons Learned from a Case Report and How to Avoid Such Pitfalls Sola Adeleke, Aidan Haslam, A. T. K. Choy, Personalized Medicine Genetic TestingMmr IhcGeneticsGenetic EpidemiologyImmunology	2022	76
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial Janet E. Brown, Kara‐Louise Royle, Walter M. Gregory, The Lancet Oncology	2023	76
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls Sibel Saya, Emma Killick, Sarah Thomas, Familial Cancer Uk Signify StudyGenetic EpidemiologyBaseline ResultsNeuroimagingTp53 Mutation Carriers	2017	67
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy Alexios S Strimpakos, David Cunningham, Christos Mikropoulos, Annals of Oncology	2009	53
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial Chris Parker, Noel W. Clarke, Adrian Cook, The Lancet	2024	43
Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer Edward J. Saunders, Tokhir Dadaev, Daniel Leongamornlert, PLoS Genetics GeneticsGenetic EpidemiologyHuman PolymorphismPathologyGenome-wide Association Study	2014	36
The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening Sarah Benafif, Holly Ní Raghallaigh, Eva McGrowder, British Journal of Urology	2021	35

Page 1